The treatment of neovascular AMD (nAMD) has been revolutionized by the introduction of anti-vascular endothelial growth factor (VEGF) agents. Though, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings, where long-term outcomes are not as good as expected. This is due to undertreatment, i.e., fewer injection and low monitoring frequency. Treatment burden due to frequent injections remains a major limitation. Long-lasting treatments provide promising solutions for this unmet need by achieving better results with less mandatory injections. This review aims to cover the current state in this field and also discuss the mechanism of action, data from pivotal trials, and safety profile of long-acting treatments in present and future, going into details about the following agents: Brolucizumab, Faricimab, Abipicar, and Conbercept.
摘要: 抗血管内皮生长因子 (VEGF) 药物的应用使新生血管性AMD (nAMD) 的治疗发生了革命性变化。但随机临床试验的结果与现实世界存在巨大差距, 临床实际的长期疗效远低于预期。这是由于治疗不足所致, 即注射次数较少以及随访频率低。其中频繁注射造成的治疗负担为主要的制约因素。而长效制剂通过减少注射次数以及获得的更好疗效, 为满足临床上述的需求提供了解决方案。本综述旨在阐述该领域的现状, 讨论长期治疗在目前和未来阶段的作用机制、重要临床试验数据和安全性, 并详细介绍以下药物: Brolucizumab、Faricimab、Abipicar和Conbercept。.